Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
Quick Facts
What This Study Found
Semaglutide reduced the risk of major adverse cardiovascular events (MACE) with hazard ratios of 0.70 for metformin users and 0.86 for non-users.
Key Numbers
How They Did This
The study involved a post hoc analysis of pooled data from the SUSTAIN 6 and PIONEER 6 trials, along with a meta-analysis of seven cardiovascular outcome trials.
Why This Research Matters
Understanding how semaglutide works for different patient groups can help tailor diabetes treatments and improve heart health outcomes. This could lead to better management strategies for patients at high cardiovascular risk.
What This Study Doesn't Tell Us
The analysis is based on post hoc data, which may limit the strength of the conclusions. Additionally, the study population may not represent all diabetes patients.
Trust & Context
- Original Title:
- Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
- Published In:
- Cardiovascular diabetology, 21(1), 64 (2022)
- Authors:
- Husain, Mansoor(4), Consoli, Agostino(4), De Remigis, Alessandra, Pettersson Meyer, Anna Sina, Rasmussen, Søren, Bain, Stephen
- Database ID:
- RPEP-06212
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06212APA
Husain, Mansoor; Consoli, Agostino; De Remigis, Alessandra; Pettersson Meyer, Anna Sina; Rasmussen, Søren; Bain, Stephen. (2022). Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.. Cardiovascular diabetology, 21(1), 64. https://doi.org/10.1186/s12933-022-01489-6
MLA
Husain, Mansoor, et al. "Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.." Cardiovascular diabetology, 2022. https://doi.org/10.1186/s12933-022-01489-6
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide reduces cardiovascular events regardless of metf..." RPEP-06212. Retrieved from https://rethinkpeptides.com/research/husain-2022-semaglutide-reduces-cardiovascular-events
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.